Results 141 to 150 of about 43,211 (293)

Drug Points: Buprenorphine: dangerous drug or overlooked therapy? [PDF]

, 1986
J R Robertson, A B Bucknall
openalex   +1 more source

Racial, ethnic, and sex disparities in buprenorphine treatment from emergency departments by discharge diagnosis

Academic Emergency Medicine, EarlyView.
Abstract Objectives Racial and sex disparities are noted in the administration and prescribing of buprenorphine from emergency departments (EDs) nationally. It is unknown whether disparities persist when accounting for the specific discharge diagnosis addressed during encounters such as opioid overdose or withdrawal.
Neeraj Chhabra, Dale Smith, Natalie Parde, Nicole Hsing‐Smith, Joseph M. Bianco, R. Andrew Taylor, Gail D'Onofrio, Niranjan S. Karnik   +7 more
wiley   +1 more source

Pruritus with sublingual buprenorphine [PDF]

, 1988
M. Woodham
openalex   +1 more source

Expanding buprenorphine prescribing in primary care: a qualitative study of the experiences of primary care providers and nurse care managers participating in the New York City buprenorphine nurse care manager initiative

Harm Reduction Journal
Background Improving access to and retention in evidence-based treatment for opioid use disorder, including buprenorphine, is a critical response to the opioid overdose crisis.
Elodie C. Warren, Nisha Beharie, Marissa Kaplan-Dobbs, Asmara Tesfaye Rogoza, Alex Harocopos   +4 more
doaj   +1 more source

Experiences and barriers to alcohol use disorder treatment among adults with and without self‐reported executive functioning challenges: A mixed‐methods study

Alcohol, Clinical and Experimental Research, EarlyView.
Participants described several challenges seeking treatment for alcohol use disorder (AUD), including multiple prior treatment attempts, delayed recognition of problematic alcohol use, and incongruent treatment expectations and experiences. Those with executive functioning challenges (53%) described the need to self‐advocate and frustration with ...
Cayley Russell, Jessica L. Wiese, Anthony C. Ruocco, Nikki Bozinoff, Raul Gonzalez, Sheila Jennings, Marco Leyton, Yuliya S. Nikolova, Josh Orson, Marc N. Potenza, Lena C. Quilty, Kevin D. Shield, Antonio Verdejo‐Garcia, Samantha Wells, Shannon Lange, The CDiA Program Study Group, Etienne Sibille, Daniel Felsky, Thomas Prevot, Yuliya Nikolova, Jeffrey Wardell, Erica Vieira, Daphne Voineskos, Isabelle Boileau, Daniel Blumberg, Christopher Bowie, Paul Fletcher, Phil Gerretsen, Ahmed Hassan, Colin Hawco, Yarissa Herman, Pamela Kaduri, Bernard Le Foll, Osnat Melamed, Leanne Quigley, Jürgen Rehm, Kevin Shield, Matthew Sloan, Victor Tang, Wei Wang   +39 more
wiley   +1 more source

Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic‐based data

Addiction, Volume 120, Issue 4, Page 745-755, April 2025.
Abstract Aims The aim of this study was to identify longitudinal trajectories of medication for opioid use disorder (MOUD) use throughout 1 year following MOUD initiation and to examine the association of trajectory membership with HIV testing among people who inject drugs in India.
Allison M. McFall, Lakshmi Ganapathi, Mihili P. Gunaratne, Aylur K. Srikrishnan, Conjeevaram K. Vasudevan, Santhanam Anand, Sunil S. Solomon, Shruti H. Mehta, Gregory M. Lucas   +8 more
wiley   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Buprenorphin [PDF]

, 2018
C. Vidal, W. R. Külpmann
openaire   +1 more source

STRUCTURE OF MORPHINE AND BUPRENORPHINE

, 1978
J.W. Downing
openalex   +1 more source

Craving self‐reports as outcome measures in drug addiction trials: A systematic review of ClinicalTrials.gov

Addiction, EarlyView.
Abstract Background and Aims The subjective experience of drug craving is characterized by an overwhelming urge to consume substances. Due to strong validity and ease of use, self‐report measures are widely employed to assess substance‐related motivational dynamics.
Matin Toulami, Keyvan Ghasemi, Parnian Rafei, Arshiya Sangchooli, Nastaran Nafissi, Arash Khojasteh Zonoozi, Hossein Mohaddes Ardabili, Mohsen Ebrahimi, Tara Rezapour, Hamed Ekhtiari   +9 more
wiley   +1 more source